Who
James M. Mock
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Moderna; Please See Remarks, Revvity.
In numbers
- Trades disclosed
- 243
- Buys
- 0
- Sells
- 16
- Bought
- $0
- Sold
- $13.0M
- Companies
- 2
- Companies where not an officer
- 0
- First trade
- 15 May 2018
- Last trade
- 5 Oct 2026
- Last filed
- 7 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Oct 2026filed 7 Oct 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —1,454 | filing |
| 5 Oct 2026filed 7 Oct 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code F | $134K704 at $190.01 | filing |
| 5 Oct 2026filed 7 Oct 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —1,454 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | $614K19,836 at $30.96 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Sold | $2.7M19,836 at $134.49 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Sold | $2.0M15,000 at $134.49 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,836 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —19,836 at $0.00 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | $614K19,836 at $30.96 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Sold | $2.7M19,836 at $134.49 | filing |
| 10 Sep 2026filed 14 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Sold | $2.0M15,000 at $134.49 | filing |
| 4 Sep 2026filed 8 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —11,797 | filing |
| 4 Sep 2026filed 8 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code F | $849K5,704 at $148.87 | filing |
| 4 Sep 2026filed 8 Sep 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,797 at $0.00 | filing |
| 4 Sep 2026filed 8 Sep 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —11,797 at $0.00 | filing |
| 4 Sep 2026filed 8 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —11,797 | filing |
| 4 Sep 2026filed 8 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code F | $849K5,704 at $148.87 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code M | —2,475 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MRNA ModernaBiotechnology | SEC FORM 4 Code F | $168K1,197 at $140.34 | filing |
| 1 Sep 2026filed 3 Sep 2026 | MRNA Modernaoption or derivative · Biotechnology | SEC FORM 4 Code M | —2,475 at $0.00 | filing |
News
Moderna (NASDAQ:MRNA) Shares Up 1.2% – Here's WhyMRNA · dailypolitical.com · 13 Oct 2026Moderna (MRNA) Was Removed From the Nasdaq-100 and Is Going Back In. What Changed?MRNA · insidermonkey.com · 9 Oct 2026Moderna (MRNA) Soars 175% in Q3: Can The Stock Keep Running?MRNA · insidermonkey.com · 5 Oct 2026
0 headlines in the last 90 days name James M. Mock; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.